Yingzi Zhen
Overview
Explore the profile of Yingzi Zhen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
63
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li Z, Li Z, Cheng X, Zhang H, Yang C, Xu Q, et al.
Res Pract Thromb Haemost
. 2025 Jan;
9(1):102639.
PMID: 39810987
Background: Low-dose (LD) or intermediate-dose (MD) immune tolerance induction (ITI) is effective in children with severe hemophilia A (SHA) with high-titer inhibitors (HTIs) and is attractive in countries with economic...
2.
Mao Q, Chen Z, Liu G, Li G, Zhen Y, Cheng X, et al.
Pediatr Investig
. 2024 Dec;
8(4):244-252.
PMID: 39720280
Importance: Emicizumab (EMI) is efficacious and safe for hemophilia A (HA) prophylaxis. However, its high cost poses a challenge in China. Objective: To explore the possibility of using reduced-dosage EMI...
3.
Zhou Y, Li Z, Liu G, Chen Z, Yao W, Li G, et al.
Clin Ther
. 2024 Oct;
46(12):1010-1015.
PMID: 39419689
Background: It is still being determined if prophylaxis (PR) has superior cost effectiveness compared with on-demand (OD) treatment for moderate or severe hemophilia A (HA) children in China. Objective/purpose: To...
4.
Yao W, Ai D, Zhang Q, Li X, Zhou M, Zhang N, et al.
Thromb Res
. 2024 Aug;
241:109110.
PMID: 39116483
Background: The Chinese Haemophilia Individualized Prophylaxis Study (CHIPS), which was launched in 2016, reported a significant reduction in haemarthrosis over a one-year study. However, its long-term efficacy requires verification. This...
5.
Li Z, Sun J, Li Z, Chen Z, Liu G, Yao W, et al.
Pediatr Investig
. 2024 Jun;
8(2):91-100.
PMID: 38910855
Importance: It remained unclear that the efficacy comparison between low-dose immune tolerance induction (LD-ITI) incorporating immunosuppressants (IS) when severe hemophilia A (SHA) patients had inhibitor-titer ≥200 Bethesda Units (BU)/mL (LD-ITI-IS...
6.
Zhen Y, Ai D, Huang K, Li G, Chen Z, Wu R
Hematology
. 2024 Feb;
29(1):2314871.
PMID: 38346146
Objective: To investigate the influence of the dead space in disposable blood sampling needle on activated partial thromboplastin time (APTT), FVIII level and pharmacokinetic (PK) profiles in children with hemophilia....
7.
Ai D, Cui C, Tang Y, Wang Y, Zhang N, Zhang C, et al.
Thromb Res
. 2023 Nov;
232:43-53.
PMID: 37931538
Background: Physical activity is a crucial part of an active lifestyle for haemophiliac children. However, the fear of bleeds has been identified as barriers to participating physical activity for haemophiliac...
8.
Wang C, Liu G, Ding Y, Li Z, Zhen Y, Cui J, et al.
Hematology
. 2023 Sep;
28(1):2250601.
PMID: 37675982
Objective: To explore the feasibility, safety and cost effectiveness of the use of peripherally inserted central catheter (PICC) in children with hemophilia A and inhibitors who underwent ITI treatment. Method:...
9.
Sun J, Li Z, Li G, Liu G, Yao W, Zhen Y, et al.
Thromb Res
. 2023 Apr;
226:56-60.
PMID: 37121012
Background: The predictors of immune tolerance induction (ITI) outcomes in hemophilia A (HA) patients with the same F8 genetic background have not yet been evaluated, although the F8 genotype is...
10.
Li Z, Sun J, Li Z, Chen Z, Liu G, Yao W, et al.
Thromb Res
. 2023 Mar;
225:33-38.
PMID: 36934482
Background: Shorter interval-time from inhibitor detection to starting immune tolerance induction (ITI) might predict better ITI outcomes for severe Hemophilia A (SHA) patients with high-risk-inhibitors. However, the prediction-impact of interval-time...